Search Results
Your search for The ASCO Post matches 17435 pages
Showing 15501 - 15550Exploring the History and Psychology of Pain: Beyond the Clinical Setting
BOOKMARKTitle: The Story of Pain: From Prayer to PainkillersAuthor: Joanna BourkePublisher: Oxford University PressPublication date: 2014Price: $34.95: hardcover, 416 page “Pain may even kill. It may overwhelm the nervous system by its mere magnitude & duration.” —Peter Mere Latham, 1871...
Will the PVS-RIPO Poliovirus Be a Game Changer in the Treatment of Recurrent Glioblastoma?
Although the idea of using viruses to target cancer cells dates back more than 100 years, technologic advances in the genetic engineering of viruses are now making it possible to safely test oncolytic virotherapy as a valid strategy against cancer cells. One type of genetically engineered virus...
MAINSAIL Trial: Worse Outcomes With Addition of Lenalidomide to Docetaxel-Prednisone in Prostate Cancer
The combination of docetaxel plus prednisone has been a standard therapy in advanced prostate cancer since 2004.1 Since then, there have been multiple randomized phase III trials comparing this standard of care with additional drug therapy. None has demonstrated improvement in outcome. Lenalidomide ...
Answers: Case Report on Chronic Myelogenous Leukemia
Question 1: In the current era of tyrosine kinase inhibitor therapy, which prognostic model is best to assess the prognosis of a person with a new diagnosis of CML? Correct Answer: D. All of the above Expert Perspective Despite not being perfect, all of these scores are reasonably effective at...
Prognostic Models in CML
Sokal Score1 Derives from a multivariate analysis of survival of 813 patients diagnosed with chronic phase CML between 1962 and 1981 (0.0116 × (age [years] – 43.4)) + (0.0345 × (spleen size [cm] – 7.51) + (0.188 × ((platelets [109/L]/700)^2 – 0.563)) + (0.0887 × (blasts [%] – 2.10)). Smaller...
Prognostic Models and Front-Line Treatment Options for Chronic-Phase Chronic Myelogenous Leukemia
The ASCO Post is pleased to present “Hematology Expert Review,” an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question, along with expert commentary, can be found in the sidebar. In this installment, we present...
Donald S. Coffey, PhD, Recognized With AACR’s Margaret Foti Award
Donald S. Coffey, PhD, was honored with the 9th Annual American Association for Cancer Research (AACR) Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR Annual Meeting 2015. Dr. Coffey, a fellow of the AACR Academy, and the Catherine Iola and J. Smith...
Stephen Grubbs, MD, to Lead ASCO’s New Clinical Affairs Department
Stephen S. Grubbs, MD, a community oncologist and Managing Partner at Medical Oncology Hematology Consultants, PA, has been named the Senior Director of ASCO’s new Clinical Affairs Department. Dr. Grubbs is a longtime ASCO member and volunteer and the Principal Investigator of the Delaware...
Karen E. Knudsen, PhD, Named Director of Sidney Kimmel Cancer Center at Thomas Jefferson University
Karen E. Knudsen, PhD, has been named the Director of the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University and the Hilary Koprowski Chair of the Department of Cancer Biology of the Sidney Kimmel Medical College of Thomas Jefferson University. Dr. Knudsen has been serving in these...
PARP Inhibitors: The First Potential Treatment of Hereditary Ovarian Cancers
Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting new classes of agents in development for the treatment of ovarian cancer. Olaparib (Lynparza), the lead oral PARP inhibitor, received accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of...
Managing Breast Cancer in 2015
Since 1990, we have seen an approximate 35% reduction in breast cancer mortality among women in the United States. Three protagonists can share this clinical success story: prevention, early detection, and better therapies. To shed light on the current state of breast cancer research and therapy,...
Richard Pazdur, MD, Receives AACR Public Service Award
Richard Pazdur, MD, was awarded the American Association of Cancer Research’s (AACR) Distinguished Public Service Award at the 2015 AACR Annual Meeting. The Association chose Dr. Pazdur for this award based on his “extraordinary, steadfast leadership in scientific and regulatory affairs” and his...
Pembrolizumab Safe and Effective in Patients With NSCLC, Especially in Those With Tumors Showing High Levels of PD-L1 Expression
Add lung cancer to the growing list of cancers that may derive benefit from immunotherapy. The KEYNOTE-001 trial found that pembrolizumab (Keytruda) achieved durable responses in a proportion of patients with non–small cell lung cancer (NSCLC) and high levels of expression of the protein PD-L1...
Genomic Analyses Point to the Potential of Personalized Care for Liver Cancer Patients
A new study presented at The International Liver Congress™ 2015 in Vienna, Austria, showed that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma, it is possible to identify specific molecular profiles. It is hoped that these ...
Cancer Rates Significantly Increased Among Patients With Hepatitis C
Results presented at The International Liver CongressTM 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV may be an increased risk of cancer. Study...
NCCN Presents Rodger Winn Award to Daniel G. Coit, MD
At the 20th Annual Conference of the National Comprehensive Cancer Network (NCCN) held in March 2015 in Hollywood, Florida, NCCN presented Daniel G. Coit, MD, with the Rodger Winn Award. The award, named for NCCN’s “founding father” of the Guidelines Program and the first Editor-in-Chief of the...
Expert Point of View: Isaac Brownell, MD, PhD
Isaac Brownell, MD, PhD, Investigator with the Dermatology Branch of the National Cancer Institute, commented on the findings of the Australian ONTRAC trial for The ASCO Post. “This is an interesting finding, and it expands on prior work showing reductions in [ultraviolet]-induced DNA damage and...
Simple Means of Preventing Nonmelanoma Skin Cancer Reported
Two daily doses of nicotinamide, a form of vitamin B3, significantly reduced the occurrence of nonmelanoma skin cancers by 23% in individuals considered at high risk for these lesions in an Australian study. Results of the phase III ONTRAC trial, which will be presented at the 2015 ASCO Annual...
Expert Point of View: Philip L. McCarthy, MD
Another exciting multiple myeloma treatment will be presented at the 2015 ASCO Annual Meeting,” Philip L. McCarthy, MD, Professor of Oncology and Director of the Blood and Marrow Transplant Center at Roswell Park Cancer Institute, Buffalo, New York, commented in an interview with The ASCO Post....
About the Contributors
Ronald Piana is an independent writer and reporter with more than 20 years of experience in oncology communications and publishing. In addition to the profiles published in this special supplemental issue of The ASCO Post, Ron has written more than 100 news and feature articles, interviews, and...
In Memoriam: John H. Saiki, MD
John “Jack” Harris Saiki, MD, Professor Emeritus at the University of New Mexico Department of Medicine, Hematology/Oncology Division, lived the history of modern-day oncology with a career spanning 44 years. In the early days of his career, with the support of a grant from the federally funded New ...
In Memoriam: Dorothy ‘Dottie’ Thomas
Dorothy “Dottie” Thomas was wife and research partner to 1990 Nobel laureate E. Donnall Thomas, MD, pioneer of the bone marrow transplant and former Director of the Clinical Research Division at Fred Hutchinson Cancer Research Center. Dr. and Mrs. Thomas formed the core of a team that proved bone...
In Memoriam: Lee W. Wattenberg, MD
One of the early giants in the field of cancer prevention, Lee W. Wattenberg, MD, published in 1966 what would be regarded as a landmark paper in the American Association for Cancer Research (AACR) journal Cancer Research. During his research, he reviewed 36 years of animal studies, looking at the...
In Memoriam: Jesse L. Steinfeld, MD
In 1971, then Surgeon General Jesse L. Steinfeld, MD, took Big Tobacco to task, stating, “Let me suggest that certain purveyors of cigarettes stop making remarks about how some young mothers in childbirth might welcome smaller babies. The mother who smokes is subjecting the unborn child to the...
In Memoriam: John Michael Fitzpatrick, MCh, FRSCI
John Michael Fitzpatrick, MCh, FRSCI, was one of Europe’s most highly regarded medical opinion leaders. He studied medicine at University College Dublin and did his clinical internship at St. Vincent’s Hospital in Dublin. While doing his residency at St. Vincent’s, he decided to become a urologist, ...
In Memoriam: Eddie Reed, MD
Eddie Reed, MD, was a pioneer in the molecular pharmacology of DNA-damaging anticancer agents and the clinical development of paclitaxel for ovarian cancer. He graduated from Yale University School of Medicine in 1979, completed his internship and residency at Stanford University in 1981, and was...
2015 Oncology Meetings
JUNE 13th International Conference on Malignant Lymphoma (ICML)June 17-20 • Lugano, Switzerland For more information: www.lymphcon.ch/imcl/index.php2 Yale ASCO® Review 2015: Highlights of the Annual MeetingJune 19 • New Haven, Connecticut For more information:...
After a Long and Distinguished Career, Robert C. Young, MD, Shows No Sign of Slowing Down
Robert C. Young, MD, ASCO Past President, longtime leader of Fox Chase Cancer Center, and an internationally recognized expert in lymphoma and ovarian cancer, is a forward-looking doctor who is confident about something not in his future: retirement. “I’ll never quit working; I’m just not wired...
Andrew C. von Eschenbach, MD, Went From the Front Lines of Cancer Care to a Bird’s-Eye View of the Changing Oncology Landscape
At the end of the day, I’m still a kid from South Philly,” Andrew C. von Eschenbach, MD, former Director of the National Cancer Institute (NCI) and Commissioner of the U.S. Food and Drug Administration (FDA), told The ASCO Post. Dr. von Eschenbach is the product of a closely knit yet culturally...
Nationally Recognized Leader in Myeloid Malignancies, Alan F. List, MD, Has High Hopes for the Future of Oncology
The Tampa Bay area of Florida is a haven for golfers and fishermen looking to unwind under the warm tropical skies. And the clean highways stretching through the scenic west coast of Florida are also a perfect excuse for weekend motorcycle enthusiasts, such as Alan F. List, MD, the President and...
Lymphoma Expert and Industry Leader Sandra J. Horning, MD, Pushes the Frontiers of Drug Development and Oncology Research
Due to childhood health issues, Sandra J. Horning, MD, formed an opinion about doctors at a young age: They were good people who helped other people. By her early teens, Dr. Horning began to ponder a career in medicine, which offered the possibility of blending her love of science with a career...
‘Father of Geriatric Oncology’ Lodovico Balducci, MD, Unearthed a New Understanding of Aging’s Effect on Cancer Treatment
At the 2007 ASCO Annual Meeting, Lodovico Balducci, MD, received the inaugural B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology. Called the “patriarch of geriatric oncology,” Dr. Balducci is widely known in the oncology community for his warm humor and thick Italian...
ASCO Announces First-Ever Clinical Trial
ASCO announced its first-ever clinical trial, which will offer patients with advanced cancer access to molecularly targeted cancer drugs and collect “real-world” data on clinical outcomes, to help learn the best uses of these drugs outside of indications approved by the U.S. Food and Drug...
Expect Questions About Preventing Fractures After Stem Cell Transplant
Does the finding that the incidence of fractures is “compellingly higher” after hematopoietic stem cell transplantation mean that physicians counseling patients about transplant should feel compelled to discuss the fracture risks? Huifang Linda Lu, MD, PhD, the corresponding author of the study...
Incidence of Fractures Is ‘Compellingly Higher’ After Hematopoietic Stem Cell Transplantation
The incidence of fractures is “compellingly higher” after receiving hematopoietic stem cell transplantation, according to a retrospective study of patients receiving transplants for treatment of multiple myeloma, other hematologic malignancies, and some solid tumors (mostly breast and ovarian) as...
Gerstner Family Foundation Commits $10 Million to Broad Institute
Broad Institute of MIT and Harvard announced a $10 million gift from the Gerstner Family Foundation, which will expand cancer research at Broad Institute and broaden collaborations with Dana-Farber/Harvard Cancer Center and Memorial Sloan Kettering Cancer Center. The research will focus on the...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Margaret Foti Recognized as 2015 Honoree of the ‘One Hundred’ by Massachusetts General Hospital Cancer Center
Margaret Foti, PhD, MD (hc), CEO of the American Association for Cancer Research (AACR), was honored for her “dedication and commitment to solving cancer through research” and for her “passionate advocacy for increased federal funding for cancer research and biomedical science,” at Massachusetts...
Meir Wetzler, MD, RPCI Leukemia Chief, Dies at Age 60
Meir Wetzler, MD, Chief of the Leukemia Section at Roswell Park Cancer Institute and University at Buffalo (UB) Professor of Medicine, died on February 23 from injuries sustained during a skiing accident in Colorado. He was 60 years old. Nationally prominent in his field, Dr. Wetzler helped set...
Carol A. Kruse, PhD, Pioneer in Brain Cancer Research and Immunotherapy, Dies at Age 61
Carol A. Kruse, PhD, a University of California, Los Angeles (UCLA) scientist and recognized leader in immunologic therapy for brain cancer, recently passed away in Los Angeles after a 6-month battle with an aggressive form of cancer. She was 61. Dr. Kruse was a UCLA Professor of Neurosurgery and...
Alan C. Sartorelli, PhD, Pioneer in Targeted Chemotherapy and AACR Past President, Dies at Age 83
Alan C. Sartorelli, PhD, Alfred Gilman Professor of Pharmacology at Yale University School of Medicine, Past President of the American Association for Cancer Research (AACR), and a Fellow of the AACR Academy, died on April 30, 2015. A pioneer in cancer chemotherapy, Dr. Sartorelli was one of the...
2015 Oncology Meetings
JUNE The International Society of Ocular Oncology (ISOO) MeetingJune 16-19 • Paris, France For more information: http://www.isoo.org 13th International Conference on Malignant Lymphoma (ICML)June 17-20 • Lugano, Switzerland For more information: www.lymphcon.ch/imcl/index.php2 Yale ASCO® Review...
Martin McMahon, PhD, Joins Research Team at Huntsman Cancer Institute
Martin McMahon, PhD, will join Huntsman Cancer Institute (HCI) at the University of Utah in August 2015 as Professor in the Department of Dermatology and HCI Senior Director of Preclinical Translation. Dr. McMahon is currently the Efim Guzik Distinguished Professor of Cancer Biology at the...
Jonathan L. Finlay, MB, ChB, FRCP, Recipient of the Elizabeth and Richard Germain Endowed Chair in Pediatric Cancer
During the Wyss Family Symposium, hosted by Nationwide Children’s Hospital May 11–12, Jonathan L. Finlay, MB, ChB, FRCP, Director of Neuro-Oncology at Nationwide Children’s, was announced as the first recipient of the Elizabeth and Richard Germain Endowed Chair in Pediatric Cancer. Dr. Finlay is...
Mount Sinai Receives $8.8 Million Grant to Further Stem Cell Research
An $8.8 million grant from the New York State Stem Cell Science Program (NYSTEM) will accelerate efforts by the Icahn School of Medicine at Mount Sinai to develop new stem cell-based treatments for chemotherapy-resistant blood cancer and other genetic blood disorders. Increasing Stem Cells...
How and When to Give Professional Feedback
Providing students and residents with feedback on their medical performance is a key element in their learning and development and ensures that high standards are met, according to Charlene M. Dewey, MD, MEd, FACP, Assistant Dean of Educator Development; Associate Professor of Medical Education and ...
Five Oncology Researchers Selected as Howard Hughes Medical Institute Investigators
The Howard Hughes Medical Institute announced 26 of the nation’s top biomedical researchers as investigators for the Institute. These scientists will receive the flexible support necessary to move their research in creative new directions. The initiative represents an investment in basic biomedical ...
Another Angiogenesis Inhibitor Shows Benefit in Metastatic Colorectal Cancer, but Where Do We Go Next?
The phase III RAISE trial—reported by Tabernero and colleagues in The Lancet Oncology1 and reviewed in this issue of The ASCO Post—demonstrated that ramucirumab (Cyramza), a fully human IgG1 monoclonal antibody to the vascular endothelial growth factor receptor 2 (VEGFR2) extracellular domain, in...
Nancy Brinker Named May LUNGevity Hero
The LUNGevity Foundation has announced Nancy Brinker, Founder and Chief of Global Strategy of Susan G. Komen, as the May LUNGevity Hero in recognition of her decades-long dedication and trailblazing work in the fight against cancer. A true pioneer of the advocacy movement, Ms. Brinker gave a...
Daniel D. Von Hoff, MD, FACP, Receives the 2015 Wallace A. Reed, MD, Award
Daniel D. Von Hoff, MD, FACP, Distinguished Professor and Physician-in-Chief of the Translational Genomics Research Institute (TGen), received the 2015 Wallace A. Reed, MD, Award on May 29 from the Arizona Medical Association (ArMA). The award recognizes his accomplishments in advancing innovative...
